

# Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG

Zehong Cao, *Member, IEEE*, Chin-Teng Lin\*, *Fellow, IEEE*, Weiping Ding, *Member, IEEE*,  
Mu-Hong Chen, Cheng-Ta Li, Tung-Ping Su\*

**Abstract** - This study explores the responses to ketamine in patients with treatment-resistant depression (TRD) using a wearable forehead electroencephalography (EEG) device. We recruited 55 outpatients with TRD who were randomized into three approximately equal-sized groups (A: 0.5 mg/kg ketamine; B: 0.2 mg/kg ketamine; and C: normal saline) under double-blind conditions. The ketamine responses were measured by EEG signals and Hamilton Depression Rating Scale (HDRS) scores. At baseline, responders showed a significantly weaker EEG theta power than did non-responders ( $p < 0.05$ ). Responders exhibited a higher EEG alpha power but lower EEG alpha asymmetry and theta cordance at post-treatment than at baseline ( $p < 0.05$ ). Furthermore, our baseline EEG predictor classified responders and non-responders with  $81.3 \pm 9.5\%$  accuracy,  $82.1 \pm 8.6\%$  sensitivity and  $91.9 \pm 7.4\%$  specificity. In conclusion, the rapid antidepressant effects of mixed doses of ketamine are associated with prefrontal EEG power, asymmetry and cordance at baseline and early post-treatment changes. The prefrontal EEG patterns at baseline may account for recognizing ketamine effects in advance. Our randomized, double-blind, placebo-controlled study provides information regarding clinical impacts on the potential targets underlying baseline identification and early changes from the effects of ketamine in patients with TRD.

**Index Terms** - Depression, EEG, Forehead, Ketamine, Predictor

This work was supported by Australian Research Council (ARC) [DP180100670, DP180100656] and the Army Research Laboratory with Cooperative Agreement [W911NF-10-2-0022]. The research was also partially sponsored by the Ministry of Science and Technology of Taiwan [MOST 106-2218-E-009 -027 -MY3, MOST 106-2221-E-009 -016 -MY2]. Additionally, the study was supported by grants from the National Scientific Council of Taiwan [NSC 101-2314-B-010-060, 102-2314-B-010-060] and the Brain Research Center of National Yang-Ming University, Taiwan.

Z. Cao and C.T. Lin are with the Center for Artificial Intelligence and Faculty of Engineering and Information Technology, University of Technology Sydney, Australia (\*corresponding to Chin-Teng.Lin@uts.edu.au).

W. Ding is with the Faculty of Engineering and Information Technology, University of Technology Sydney, Australia and also with School of Computer Science and Technology, Nantong University, Nantong, China.

M.H. Chen and C.T. Li are with Taipei Veterans General Hospital, Taipei, Taiwan.

T.P. Su is with Cheng-Hsin General Hospital, Taipei, Taiwan, and also with Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan. (\*corresponding to tomsu0402@gmail.com).

## I. INTRODUCTION

DEPRESSION is a common affective disorder with a high prevalence worldwide (4.5% - 37.4%), and the incidence of major depressive disorder ranges from 4.6% to 9.3%. Current traditional antidepressants, including serotonin selective reuptake inhibitors, serotonin norepinephrine reuptake inhibitors and norepinephrine and dopamine reuptake inhibitors, have been used to treat depression in single or combined medications. Approximately 30-40% of patients with major depression do not respond to the traditional antidepressants, and a patient with major depression who does not respond to at least two clinical trials of traditional antidepressants under an adequate period is regarded as having treatment-resistant depression (TRD) [1]. Patients with TRD have traditionally been defined as having no response or an inadequate response; however, recent clinical studies have shown significant improvements in depressive symptoms after a low-dose ketamine treatment. Ketamine, an NMDA receptor antagonist, is different from traditional antidepressants, which all act on monoamine systems. In contrast, ketamine acts on the glutamate system of the brain. The discovery and replication of the rapid and robust antidepressant effects of ketamine for TRD symptoms may constitute an important advance, addressing some limitations, such as longer latency to become effective, for current antidepressant treatments. Additionally, low-dose ketamine has been noted to have robust and rapid antidepressant effects, specifically in patients with TRD [2-4].

Depressive symptoms are linked with brain cortical abnormalities, and the prefrontal cortex (PFC) is critically involved in the neuro-circuitry of depression [5]. Depressive disorders are correlated with a reduction in dorsolateral PFC grey matter volumes and unique directional changes in the prefrontal cortex [6, 7]. Furthermore, as shown in our previous studies, patients with TRD demonstrated that glucose metabolism of the PFC was correlated with ketamine responses [4], and these patients continued to present abnormal glucose metabolism in the PFC after aggressive treatments [8, 9]. Therefore, the PFC is a potential indicator that reflects the neurophysiological activity of patients with TRD.

Electroencephalography (EEG), which features non-invasive electrodes placed along the scalp, is an electrophysiological monitoring method used to record the spontaneous electrical activity of the brain [10]. EEG has been widely used to study antidepressant treatment responses in many clinics due to its broad availability and cost-

effectiveness [11, 12]. The development of dry sensors has made wearable EEG headbands with dry electrodes more convenient for measuring EEG signals than conventional EEG headsets with wet electrodes. Dry electrodes avoid the use of conductive gel and skin preparation while transmitting brainwaves that are encountered with wet electrodes [13, 14].

The relationship between the antidepressant response and prefrontal EEG dynamics, particularly measurements derived from theta and alpha activity, has attracted significant interest [12, 15-17]. Alpha activity has an inhibitory effect on cortical network activity; thus, increased alpha power has been observed in depressed patients who respond to antidepressant treatment [18]. Some studies also reported antidepressant treatment responses in association with hemispheric asymmetry, a relative measure of the difference in EEG alpha power between the right and left prefrontal regions that reflects relatively lateralized cortical activity [19]. While left versus right hemispheric activation was associated with treatment response, a body of literature has raised the possibility of hemispheric asymmetry in the alpha band [11, 18, 20, 21]. Similarly, conflicting studies have investigated theta activity and have reported increased absolute theta power [22] or decreased relative theta power [17] associated with treatment response. To identify the emergent effectiveness of antidepressant therapy, theta cordance [23] was derived from both absolute and relative theta power. Prior studies have shown decreased frontal theta cordance after antidepressant treatment [24, 25]. Additionally, a “pre-exposure EEG” may capture trait aspects of psychological dysfunction [26], suggesting that a baseline (pretreatment) EEG has the potential to predict the effects of antidepressants on an individual. These EEG patterns, which are correlated with response to antidepressants, potentially represent the neurophysiological activities in patients with TRD.

The literature review shows that the derived EEG features demonstrated various trends from the baseline to post-treatment that may be associated with different types of antidepressants. However, whether the responses of TRD to ketamine involve the dynamics of prefrontal EEG and whether the discriminative EEG can be used as a potential feature to predict ketamine response remain unclear. The novelty of this study involves the dynamics of prefrontal EEG to investigate responses of patients with TRD to ketamine treatment instead of traditional antidepressants. Because antidepressants exert their effects on PFC activation and EEG dynamics, an *a priori* hypothesis is that the rapid antidepressant effects of different doses of ketamine, similar to the time-dependent effects of some traditional antidepressants, are correlated with baseline and early changes in EEG patterns in the prefrontal area. Consistent with previous studies [27-29], our study proposes to investigate prefrontal EEG patterns (e.g., power, asymmetry and cordance) at the baseline level (-10 to 0 min) and early post-treatment changes (240-250 min after the infusion) to determine signatures of the ketamine response under randomized, double-blind, placebo-controlled conditions. Additionally, the discriminative EEG patterns at baseline may help TRD patients understand ketamine’s effects and

could potentially be used in daily life via a wearable forehead EEG device.

This paper is organized as follows. First, Section II introduces the participant recruitment, experimental procedures, data processing and statistical analysis used in this study. Section III presents the experimental results, including the demographic characteristics and clinical and treatment responses, comparisons between groups, and predictor performance. Section V discusses the experimental results, future directions and limitations. Section VI provides the conclusion.

## II. MATERIALS AND METHODS

### A. Subjects

Outpatients with depression were recruited by the Psychiatric Department of Taipei Veterans General Hospital (VGH). Patient diagnoses were based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSM-IV-TR) for the diagnosis of major depressive disorder. In addition, the included patients did not have major medical or neurological illnesses. The enrolled patients were required to have a poor treatment history with at least two different antidepressants (with sufficient dosages and treatment periods) and at least one invalid effort with adequate antidepressant treatment during their current depressive episode to ensure that each subject was resistant to the antidepressant medications. Patients were excluded if they received a structured diagnostic Mini International Neuropsychiatric Interview (MINI) [30] conducted by a board-certified psychiatrist (TPS) to confirm the diagnosis.

The Hamilton Depression Rating Scale-17 (HDRS-17) [31] is the most widely used clinician-administered depression assessment scale for evaluating the antidepressants’ effects. The questionnaire, designed for adults, is used to rate the severity of a patient’s depression by probing mood, feelings of guilt, suicidal ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms. The original version contains 17 items, pertaining to symptoms of depression experienced over the past week. A score of 0–7 is considered to be normal, while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.

Patients with a history of bipolar disorder, psychotic depression or substance/alcohol abuse or a score of less than 18 on the HDRS-17 at screening and less than 13 at the start of infusion. Comorbid Axis I diagnoses of anxiety disorders were permitted due to their ubiquity in patients with major depressive disorder (MDD). This study was approved by the Institutional Review Board at the Taipei VGH (2012-04-037B), and informed consent was obtained from all the subjects before entry into the study. This clinical trial was registered with the UMIN Clinical Trials Registry (UMIN000016985) on 30 June 2016. Additionally, all the experimental procedures were performed in accordance with the relevant guidelines and regulations.




Figure 1. EEG analytical procedures used for the ketamine experiment. (A) Wearable EEG device; (B) Ketamine infusion and EEG & HDRS recordings.

### B. Experimental Procedures

Each patient received a clinical assessment, including a psychiatric profile, medical history and assessment of medication use. Patients with TRD were divided into three subgroups at an approximate 1:1:1 ratio: group A-0.5 mg/kg ketamine, group B-0.2 mg/kg ketamine, and group C-normal saline (NS). This subgroup allocation was conducted under randomized and double-blind conditions by an independent nurse who was not involved in our study. Experiments were performed in a quiet, dimly lit room at psychiatric inpatient unit D020 of Taipei VGH. During the first two minutes of the experiment, the patients were instructed to take several deep breaths while they adapted to the environment. A specific wearable EEG recording system (Fig. 1A) called the “Mind-o-4S Jellyfish” (Brain Rhythm Inc., Zhubei District, Hsinchu, Taiwan), which used a 16-bit quantization level at a sampling rate of 512 Hz, was used in this study; the system contained four dry electrodes (Fp1, Fp2, AF7 and AF8) in the prefrontal region, a reference electrode (A2) [13, 14] and a built-in real-time EEG signal enhancement to remove artefacts [32]. These dry electrodes are more convenient for measuring EEG signals than are conventional wet electrodes, and they are preferred because they avoid the use of conductive gel and skin preparation while achieving a signal quality comparable to that of wet electrodes [13, 14].

Next, as shown in Fig. 1B, patients were instructed to close their eyes as EEG signals were recorded for approximately 10 min (baseline, the 1<sup>st</sup> session). Subsequently, an infusion of 0.5 mg/kg ketamine, 0.2 mg/kg ketamine or NS was administered over the course of 40 min. Notably, the patients always experienced difficulty in sitting still or had a headache during ketamine administration; therefore, EEG signals were not recorded during that period. Subjects were also allowed to sit in the rest area and to read books to avoid fatigue or drowsiness. Later, closed-eye EEG signals were recorded during a second 10-min session to evaluate the effects of ketamine at 240-min post-infusion. Additionally, an experienced EEG specialist monitored the experimental conditions during the EEG recordings (e.g., ensuring that the location of the wearable EEG device did not shift).

In addition, quantitative depressive symptom ratings were recorded at 0 min (baseline), 40 min (end of the

infusion), 80 min, 120 min, 240 min, 24 hours (on day 2), day 3, day 4, day 5, day 6, day 7 (one week) and day 14 (two weeks) post-treatment using the HDRS-17 (Fig. 1B). A “responder” was defined as an individual having at least a 45% reduction in HDRS-17 score from baseline to 240-min post-treatment, and all the others were classified as non-responders.

### C. EEG Data Processing

The EEG data were analyzed with EEGLAB, an open-source MATLAB toolbox for electrophysiological signal processing and analysis [33]. The analytical procedures used to process EEG signals included bandpass filtering, time-frequency analysis, power estimation, asymmetry calculation, Cordance assessment and antidepressant treatment response (ATR) measurement.

Experienced EEG specialists were required to inspect the collected data to ensure that the raw EEG data did not have interference from artefacts despite the fact that the wearable EEG device has a built-in function to remove artefacts via real-time EEG signal enhancement. The EEG data were then bandpass-filtered from 1 to 12 Hz using a zero-phase finite impulse response filter. The processed EEG signals were subjected to further analysis.

#### a. EEG power

Processed time-series EEG data were transformed into the frequency domain with a 256-point fast Fourier transform using Welch’s method. Specifically, 10-min spans of data were analyzed with a 256-point moving window and a 128-point overlap. To obtain high-frequency resolution, zero-padding was used to extend the length of the window. Windowed data were extended to 512 points by zero padding to calculate the power spectra, yielding an estimation of the power spectra from 1 to 12 Hz (frequency resolution: 0.5 Hz). The power spectra ( $P$ ) of these windows were averaged and converted to a logarithmic scale. The relative EEG power was defined as the percentage of absolute power in any frequency band compared with the total power of the entire EEG spectrum.

The absolute power was marked as  $P_{c,f}$ , and the relative power was expressed as

$$\widehat{P}_{c,f} = P_{c,f} / P_{c,f'} \quad (1)$$

where  $c$  is the channel, and  $f$  and  $f'$  are the specific frequency band and all bands, respectively.

Of note, the absolute and relative EEG powers of four prefrontal channels were calculated from the delta (1–3.5 Hz), theta (4–7.5 Hz), lower alpha (8–10 Hz) and upper alpha (10.5–12 Hz) bands.

#### b. EEG alpha asymmetry

We used the mid-prefrontal (Fp1/Fp2) and mid-lateral (AF7/AF8) hemispheric asymmetry index to establish a relative measure of the difference in EEG (lower and upper) alpha power between the right and left forehead areas. The formula used to calculate the left-right asymmetry score was defined as

$$A_{LR} = |(P_L - P_R) / (P_L + P_R)| \quad (2)$$

where  $P_L$  is the (lower/upper) alpha power that is left-lateralized at the baseline or post-treatment observations, and  $P_R$  is the corresponding right-lateralized power.

#### c. EEG theta cordance

Theta cordance combines information from both absolute and relative power in the EEG theta band, which is less influenced by age, gender and severity associated with baseline depression.

The absolute and relative EEG power from Equation (1) were normalized, which was expressed as follows:

$$\tilde{P}_{A(c,f)} = P_{c,f} / \max(P_c) \quad (3)$$

$$\tilde{P}_{R(c,f)} = \hat{P}_{c,f} / \max(\hat{P}_c) \quad (4)$$

where  $\max(P_c)$  and  $\max(\hat{P}_c)$  represent the maximum absolute power and maximum relative power, respectively.

The theta cordance was then calculated as follows:

$$Cordance_{c,f} = (\tilde{P}_{A(c,f)} - 0.5) + (\tilde{P}_{R(c,f)} - 0.5) \quad (5)$$

#### D. EEG Predictors

The significant features from the EEG power analyses were treated as characteristic inputs to build a classification (prediction) model to distinguish ketamine effects at baseline. We considered a three-fold cross validation (66.7% training set and 33.3% testing set) to evaluate the classification performance of mixed ketamine groups. Then, considering the prediction performances for ketamine groups A and B separately, we measured the leave-one-subject-out cross-validation to evaluate the classification performances in group A or B. The classification model was built by EEG features from the training set and then examined via the

testing set. To predict ketamine effects, we classified the responders and non-responders using EEG features at baseline. In this study, we employed various machine learning classifiers to identify the EEG features that could be used for comparison; these classifiers included linear discriminant analysis (LDA), nearest mean classifier (NMSC), k-nearest neighbors (k-NN with  $k = 3$ ), Parzen density estimation (PARZEN), perceptron classifier (PERLC), discriminative restricted Boltzmann machine (DRBMC) and support vector machine with radial basis function (SVMRBF) (PRTools, <http://prtools.org/>; LIBSVM toolbox, <http://www.csie.ntu.edu.tw/~cjlin/libsvm/>). In addition, we employed assessment criteria in medical screening (sensitivity and specificity) and pattern recognition (recall, precision and F-measure) to evaluate the performance of the proposed predictors.

#### E. Statistical Analysis

We analyzed differences between the groups (A: 0.5 mg/kg ketamine, B: 0.2 mg/kg ketamine and C: NS) regarding demographics, clinical profiles and treatment responses using one-way ANOVA tests and following correction of multiple comparisons by sharpened Bonferroni procedure [34]. To investigate the differences in EEG power between responders and non-responders at baseline, we compared the EEG power values for the groups using the Wilcoxon rank-sum test to determine whether two independent samples (sample size  $< 30$ ) of responders and non-responders had the same distribution. To determine EEG changes between baseline and post-infusion time points, we compared pre- and post-infusion EEG power and asymmetry values using the Wilcoxon signed-rank test. The significance level was set to  $p < 0.05$ . Additionally, since there are many potential EEG parameters to examine regarding ketamine responses, the

**Table I. Demographics, Clinical Profiles and Treatment Responses of the Ketamine and NS Groups**

Characteristics	Antidepressant Groups			Bonferroni-adjusted One-way ANOVA <i>p</i>
	Ketamine ( <i>n</i> = 37)			
	A: 0.5 mg/kg ( <i>n</i> = 18)	B: 0.2 mg/kg ( <i>n</i> = 19)	C: NS ( <i>n</i> = 18)	
<i>Demographics</i>				
Sex, F:M	16:2	16:3	13:5	0.232
Age, yrs	46.5 ± 11.6	48.1 ± 12.7	50.0 ± 7.6	0.340
<i>Clinical profiles</i>				
Disease duration, yrs	12.3 ± 8.3	12.6 ± 9.3	11.5 ± 7.3	0.686
Psychiatric comorbidities <sup>a</sup>	2.0 ± 1.6	2.1 ± 1.4	2.4 ± 1.5	0.658
Current antidepressants <sup>b</sup>	1.7 ± 0.7	1.8 ± 0.8	1.5 ± 0.7	0.718
<b>HDRS-17 Scores</b>				
	Group A and B ( <i>n</i> = 37)		Group C ( <i>x</i> ) ( <i>n</i> = 18)	
<i>Time points</i>	<i>Responders (x)</i>		<i>Non-responders</i>	
<b>0 min (baseline)</b>	22.4 ± 4.3 ( <i>x</i> = 0)	[ <i>p</i> <sup>1</sup> = 0.485; <i>p</i> <sup>2</sup> = 0.556]	24.8 ± 4.2	23.7 ± 4.5 ( <i>x</i> = 0)
40 min after treatment	13.6 ± 4.2 ( <i>x</i> = 9)	[ <i>p</i> <sup>1</sup> = 0.363; <i>p</i> <sup>2</sup> = 0.335]	20.2 ± 4.6	20.9 ± 4.8 ( <i>x</i> = 0)
120 min after treatment	11.7 ± 4.5 ( <i>x</i> = 11)	[ <i>p</i> <sup>1</sup> = 0.043; <i>p</i> <sup>2</sup> = 0.048]*	21.3 ± 4.9	20.1 ± 5.4 ( <i>x</i> = 0)
<b>240 min after treatment</b>	10.6 ± 3.7 ( <b><i>x</i> = 16</b> )	[ <i>p</i> <sup>1</sup> = 0.037; <i>p</i> <sup>2</sup> = 0.041]*	20.8 ± 5.3	19.2 ± 6.1 ( <b><i>x</i> = 2</b> )
Day 2 (24 hours) after treatment	10.1 ± 3.9 ( <i>x</i> = 9)	[ <i>p</i> <sup>1</sup> = 0.043; <i>p</i> <sup>2</sup> = 0.046]*	19.2 ± 5.7	18.9 ± 5.9 ( <i>x</i> = 1)
Day 3 after treatment	10.3 ± 4.4 ( <i>x</i> = 9)	[ <i>p</i> <sup>1</sup> = 0.051; <i>p</i> <sup>2</sup> = 0.052]	19.4 ± 6.3	19.1 ± 6.1 ( <i>x</i> = 1)
Day 5 after treatment	10.7 ± 4.6 ( <i>x</i> = 5)	[ <i>p</i> <sup>1</sup> = 0.204; <i>p</i> <sup>2</sup> = 0.198]	19.2 ± 6.2	19.2 ± 5.9 ( <i>x</i> = 0)
Day 7 after treatment	12.5 ± 5.0 ( <i>x</i> = 3)	[ <i>p</i> <sup>1</sup> = 0.438; <i>p</i> <sup>2</sup> = 0.429]	19.7 ± 6.1	19.7 ± 5.8 ( <i>x</i> = 0)

$x$ : Number of subjects who showed a response to ketamine.

<sup>a</sup> Psychiatric comorbidities: chronic dysthymia, generalized anxiety disorder, panic disorder, social phobia and post-traumatic stress disorder.

<sup>b</sup> Number of antidepressants used, including regular antidepressants, mood stabilizers and atypical antipsychotics.

\*  $p < 0.05$  using Bonferroni-adjusted Tukey's post hoc test (responders vs. non-responders or the NS group).  $p^1$  indicates Bonferroni-adjusted  $p$  values for describing HDRS-17 differences between responders and non-responders, and  $p^2$  indicates Bonferroni-adjusted  $p$  values for describing HDRS-17 differences between responders and the NS group.

experiment-wise error may be significantly inflated. Given the number of comparisons analyzed, Hochberg's sharpened Bonferroni [34] adjusted significant values (primary significance level  $p < 0.05$  and secondary significance level  $p < 0.025$ ) were used to reduce Type I error. Of note, the significantly different EEG baseline power ( $p < 0.05$ ) between responders and non-responders was treated as a characteristic input to build a classification (prediction) model. Statistical analyses were performed using the SPSS software package (version 15.0) and MATLAB (2011a) Bioinformatics Toolbox.

### III. RESULTS

#### A. Demographic, Clinical and Treatment-Response Characteristics

Fifty-five outpatients with TRD were enrolled in this study from October 2014 to April 2016, of whom 18, 19 and

18 patients received infusions of 0.5 mg/kg ketamine (group A), 0.2 mg/kg ketamine (group B) and normal saline (NS; group C), respectively. As shown in Table I, the demographic and clinical characteristics, including age, gender and clinical profiles (disease duration, psychiatric comorbidities and number of current antidepressants), were similar among the three groups. The concomitant medication regimens consisted of one antidepressant (36.4%), more than 2 antidepressants (21.8%) and a combination of antidepressants, mood stabilizers and atypical antipsychotics (41.8%). According to the MINI diagnosis, the most common psychiatric comorbidities were chronic dysthymia (52.7%), generalized anxiety disorder (GAD, 49.1%), panic disorder (32.7%), social phobia (10.9%) and post-traumatic stress disorder (10.9%). Approximately 54.5% of patients had 2 or more comorbid psychiatric disorders. No significant differences in the prevalence of concomitant medications or comorbid psychiatric diseases were observed among the three groups.

As shown in Fig. 2, we periodically recorded changes in HDRS-17 item scores for depression severity from baseline (pretreatment) to 14 days post-treatment throughout the study. Notably, the ketamine responders showed a substantially greater improvement. Specifically, we did not observe a significant difference among groups A, B and C at baseline, but responders had significantly lower HDRS

scores than did non-responders or NS subjects at 120 min, 240 min, 24 hours (on day 2) and day 3 post-treatment. According to the HDRS-17 estimates shown in Table I, a maximum of 16 responders was observed in the two ketamine groups (A: 0.5 mg/kg,  $n = 11$ ; B: 0.2 mg/kg,  $n = 5$ ) at 240-min post-treatment. Specifically, 11 of 18 (61%) patients infused with 0.5 mg/kg ketamine showed a significant response at 240-min post-treatment, while only 5 of 19 (26%) patients infused with 0.2 mg/kg ketamine showed a significant response at this time point.

Nevertheless, only a few subjects in the NS group ( $n = 2$ ) displayed an effective response during the same period. The HDRS-17 estimates also revealed that the most effective treatment outcome among all the time points occurred at 240-min post-ketamine infusion. Furthermore, comparing the HDRS-17 scores at baseline and at 240-min post-treatment indicated that the severity of depression (mean  $\pm$  standard deviation (SD)) in the ketamine responders decreased from  $22.4 \pm 4.3$  to  $10.6 \pm 2.7$  with a response rate of  $52.7 \pm 7.3\%$ ; the severity in the ketamine non-responders decreased from  $24.8 \pm 4.2$  to  $20.8 \pm 5.3$  with a response rate of  $18.4 \pm 11.6\%$ ; and the severity in the NS group decreased from  $23.7 \pm 4.5$  to  $19.2 \pm 6.1$  with a response rate of  $20.1 \pm 13.0\%$ . Notably, the severity of depression in responders showed a significantly greater improvement than that in non-responders or NS subjects ( $p < 0.05$ ).

#### B. Baseline Comparisons of EEG Power

As shown in Fig. 3, we investigated baseline comparisons (pretreatment) between responders and non-responders by combing the continuous power spectra of all channels (AF7, Fp1, Fp2 and AF8). Compared with the non-responders, the responders showed lower relative EEG theta and low alpha power in the 0.5 mg/kg ketamine group ( $p < 0.05$ ). There was a lack of significant findings for the 0.2 mg/kg ketamine group.

As indicated by the baseline comparisons of mean power spectra shown in Table II, compared with the non-responders in group A (0.5 mg/kg ketamine), the responders in group A had significantly ( $p < 0.05$ ) weaker relative EEG power in the theta band on the AF7 and Fp2 channels, as well as a decreasing trend towards a relatively low alpha EEG power on the AF7 and Fp2 channels. For the baseline comparisons in group B (0.2 mg/kg ketamine), the responders showed




Figure 2. Changes in HDRS-17 scores from baseline to 14 days after the infusion.




Figure 3. Baseline comparisons of EEG power for ketamine groups (left: 0.5 mg/kg, right: 0.2 mg/kg). Of note, the red and blue traces represent the mean  $\pm$  SD of the EEG power in responders and non-responders, respectively.

Table II. Relative EEG Power: Baseline Comparisons in Ketamine Groups

Ketamine Groups (n = 37)							
Relative Power	A: 0.5 mg/kg dose (n = 18)			B: 0.2 mg/kg dose (n = 19)			<i>p</i> <sup>b</sup>
	Responders (n = 11)	Non-responders (n = 7)	<i>p</i>	Responders (n = 5)	Non-responders (n = 14)	<i>p</i>	
AF7							
Delta	1.40 ± 0.26	1.34 ± 0.14	N	1.42 ± 0.18	1.33 ± 0.17	N	N
Theta	0.89 ± 0.06	0.95 ± 0.06	<b>0.042</b>	0.91 ± 0.05	0.92 ± 0.07	N	N
Low Alpha	0.81 ± 0.11	0.91 ± 0.09	0.045 <sup>a</sup>	0.83 ± 0.25	0.90 ± 0.26	N	N
High Alpha	0.76 ± 0.13	0.78 ± 0.08	N	0.79 ± 0.20	0.75 ± 0.14	N	N
Fp1							
Delta	1.41 ± 0.21	1.33 ± 0.12	N	1.41 ± 0.19	1.32 ± 0.16	N	N
Theta	0.89 ± 0.06	0.95 ± 0.06	N	0.93 ± 0.06	0.94 ± 0.07	N	<b>0.038</b>
Low Alpha	0.84 ± 0.10	0.90 ± 0.11	N	0.85 ± 0.20	0.99 ± 0.25	N	N
High Alpha	0.74 ± 0.09	0.77 ± 0.08	N	0.80 ± 0.20	0.73 ± 0.15	N	N
Fp2							
Delta	1.42 ± 0.20	1.28 ± 0.15	N	1.42 ± 0.20	1.28 ± 0.16	N	N
Theta	0.88 ± 0.03	0.96 ± 0.06	<b>0.035</b>	0.91 ± 0.04	0.95 ± 0.05	<b>0.028</b>	<b>0.042</b>
Low Alpha	0.81 ± 0.11	0.92 ± 0.07	0.039 <sup>a</sup>	0.83 ± 0.18	0.91 ± 0.27	N	N
High Alpha	0.74 ± 0.12	0.81 ± 0.09	N	0.79 ± 0.18	0.78 ± 0.17	N	N
AF8							
Delta	1.41 ± 0.26	1.32 ± 0.17	N	1.40 ± 0.21	1.30 ± 0.18	N	N
Theta	0.89 ± 0.06	0.95 ± 0.07	N	0.92 ± 0.07	0.93 ± 0.05	N	N
Low Alpha	0.82 ± 0.13	0.91 ± 0.06	N	0.84 ± 0.21	0.90 ± 0.26	N	N
High Alpha	0.75 ± 0.15	0.78 ± 0.12	N	0.80 ± 0.15	0.76 ± 0.16	N	N

Delta: (1-3.5 Hz) / (1-12 Hz) EEG power (dB).

Theta: (4-7.5 Hz) / (1-12 Hz) EEG power (dB).

Low Alpha: (8-10 Hz) / (1-12 Hz) EEG power (dB).

High Alpha: (10.5-12 Hz) / (1-12 Hz) EEG power (dB).

*p* value: measured using the Wilcoxon rank-sum test with a significant *p* value < 0.05.1) N: Not significant (*p* ≥ .05).2) Significance values were adjusted using a Sharpened Bonferroni correction for multiple comparisons (primary significance level *p* < 0.05 and secondary significance level *p* < 0.025).<sup>a</sup> Not statistically significant after sharpened Bonferroni adjustment.<sup>b</sup> Comparisons of responders between groups A and B.

significantly (*p* < 0.05) weaker relative EEG power in the theta band on the Fp2 channel than did the non-responders. No differences were observed in the relative EEG power in the delta and high alpha bands between the responders and non-responders in groups A or B. Additionally, the responders in group A showed significantly (*p* < 0.05) higher relative EEG power in the theta band on the Fp1 and Fp2 channels than did the responders in group B, indicating that for some patients, only a low ketamine dose (0.2 mg/kg) is needed to elicit a significant effect on EEG power.

### C. Comparisons of Baseline and 240 min Post-treatment

As shown in Table III, groups A and B were combined, and the responders and non-responders in the group were regarded as the active ketamine group and inactive ketamine group, respectively. We compared the relative EEG power before and after ketamine or NS infusion (0 min vs. 240 min). The EEG power of the active ketamine group showed a significant (*p* < 0.05) increase in the low alpha band on the AF7, Fp1, Fp2 and AF8 channels at 240-min post-treatment compared with that at baseline (pretreatment), but no changes were observed in the delta or theta band. The relative

EEG power in the inactive ketamine and placebo groups generally did not differ from baseline values.

Table III also shows differences in hemispheric asymmetry in the low and high alpha bands from the baseline to 240min post-treatment observations. The midline (Fp1-Fp2) low alpha asymmetry of the active ketamine group showed a significant decrease (*p* = 0.042, from 0.11 ± 0.12 to 0.03 ± 0.02) after ketamine treatment (*p* < 0.05), whereas the hemispheric alpha asymmetry of the inactive ketamine group and the NS group was similar between baseline and post-treatment observation.

Additionally, we compared the EEG theta cordance from baseline to 240-min post-treatment (Table III). Responders showed significantly decreased EEG theta cordance in all the channels (*p* < 0.05). Specifically, after ketamine treatment, responders showed a significantly decreased EEG theta cordance in AF7 (*p* = 0.041, from 1.55 ± 0.07 to 1.42 ± 0.08), Fp1 (*p* = 0.014, from 1.54 ± 0.05 to 1.41 ± 0.06), Fp2 (*p* = 0.023, from 1.53 ± 0.05 to 1.42 ± 0.06) and AF8 (*p* = 0.046, from 1.55 ± 0.08 to 1.41 ± 0.08), while the EEG theta cordance of the inactive ketamine group or the NS group showed no significant differences. Briefly, early changes in EEG power, asymmetry and cordance were observed in the

\*\*\*\*\*

**Table III. Relative EEG Power, Alpha Asymmetry & Theta Cordance: Baseline vs. 240-min Post-treatment**

<i>0.5 or 0.2 mg/kg ketamine dose</i>									
<i>Index</i>	<i>Active group: Responders (n = 16)</i>			<i>Inactive group: Non-responders (n = 21)</i>			<i>NS (n = 18)</i>		
	<i>0 min<sup>b</sup></i>	<i>240 min<sup>c</sup></i>	<i>p</i>	<i>0 min<sup>b</sup></i>	<i>240 min<sup>c</sup></i>	<i>p</i>	<i>0 min<sup>b</sup></i>	<i>240 min<sup>c</sup></i>	<i>p</i>
<b>Relative Power</b>									
<b>AF7</b>									
Delta	1.40 ± 0.26	1.36 ± 0.26	N	1.31 ± 0.16	1.29 ± 0.21	N	1.16 ± 0.61	1.10 ± 0.57	N
Theta	0.90 ± 0.07	0.88 ± 0.08	N	0.95 ± 0.06	0.95 ± 0.13	N	0.91 ± 0.11	0.91 ± 0.11	N
Low Alpha	0.85 ± 0.15	0.96 ± 0.23	<b>0.010</b>	0.99 ± 0.25	0.97 ± 0.18	N	1.01 ± 0.27	1.08 ± 0.21	N
High Alpha	0.80 ± 0.19	0.85 ± 0.21	N	0.74 ± 0.12	0.78 ± 0.17	N	0.97 ± 0.58	1.01 ± 0.52	N
<b>Fp1</b>									
Delta	1.38 ± 0.21	1.31 ± 0.25	N	1.32 ± 0.12	1.29 ± 0.17	N	1.21 ± 0.56	1.18 ± 0.44	N
Theta	0.93 ± 0.08	0.91 ± 0.08	N	0.96 ± 0.06	0.97 ± 0.12	N	0.95 ± 0.11	0.93 ± 0.10	N
Low Alpha	0.87 ± 0.14	0.96 ± 0.18	<b>0.023</b>	0.98 ± 0.20	0.97 ± 0.18	N	0.95 ± 0.25	1.00 ± 0.17	N
High Alpha	0.78 ± 0.13	0.84 ± 0.19	N	0.73 ± 0.13	0.75 ± 0.16	N	0.88 ± 0.48	0.92 ± 0.43	N
<b>Fp2</b>									
Delta	1.41 ± 0.20	1.30 ± 0.22	N	1.26 ± 0.15	1.25 ± 0.19	N	1.10 ± 0.64	1.11 ± 0.50	N
Theta	0.90 ± 0.08	0.90 ± 0.09	N	0.97 ± 0.07	0.97 ± 0.12	N	0.96 ± 0.08	0.93 ± 0.22	N
Low Alpha	0.85 ± 0.15	0.98 ± 0.21	<b>0.020</b>	1.00 ± 0.22	1.00 ± 0.20	N	1.01 ± 0.29	1.06 ± 0.19	N
High Alpha	0.80 ± 0.13	0.87 ± 0.23	<b>0.023</b>	0.75 ± 0.16	0.79 ± 0.15	N	0.95 ± 0.57	0.98 ± 0.52	N
<b>AF8</b>									
Delta	1.39 ± 0.43	1.30 ± 0.20	N	1.30 ± 0.17	1.28 ± 0.19	N	1.59 ± 1.20	2.01 ± 5.63	N
Theta	0.92 ± 0.12	0.90 ± 0.08	N	0.95 ± 0.08	0.96 ± 0.11	N	0.95 ± 0.14	0.89 ± 0.20	N
Low Alpha	0.85 ± 0.16	0.98 ± 0.19	<b>0.011</b>	0.99 ± 0.22	0.97 ± 0.19	N	0.82 ± 0.68	0.50 ± 0.12	N
High Alpha	0.80 ± 0.17	0.86 ± 0.15	<b>0.045<sup>a</sup></b>	0.76 ± 0.12	0.79 ± 0.15	N	0.53 ± 1.14	0.36 ± 4.29	N
<b>Alpha Asymmetry</b>									
<b>AF8 -AF7</b>									
Low Alpha	0.12 ± 0.14	0.08 ± 0.12	N	0.06 ± 0.10	0.07 ± 0.09	N	0.06 ± 0.07	0.03 ± 0.03	N
High Alpha	0.11 ± 0.12	0.05 ± 0.04	N	0.10 ± 0.12	0.07 ± 0.08	N	0.07 ± 0.08	0.04 ± 0.04	N
<b>Fp2 -Fp1</b>									
Low Alpha	0.11 ± 0.12	0.03 ± 0.02	<b>0.042</b>	0.09 ± 0.11	0.06 ± 0.07	N	0.43 ± 1.48	0.09 ± 0.11	N
High Alpha	0.13 ± 0.18	0.07 ± 0.07	N	0.08 ± 0.10	0.10 ± 0.11	N	0.19 ± 0.43	0.10 ± 0.12	N
<b>Theta Cordance</b>									
<b>AF7</b>	1.55 ± 0.07	1.42 ± 0.08	<b>0.041<sup>a</sup></b>	1.48 ± 0.08	1.39 ± 0.09	N	1.48 ± 0.08	1.41 ± 0.08	N
<b>Fp1</b>	1.54 ± 0.05	1.41 ± 0.06	<b>0.014</b>	1.50 ± 0.06	1.41 ± 0.07	N	1.51 ± 0.07	1.41 ± 0.09	N
<b>Fp2</b>	1.53 ± 0.05	1.42 ± 0.06	<b>0.023</b>	1.49 ± 0.07	1.40 ± 0.07	N	1.50 ± 0.06	1.40 ± 0.08	N
<b>AF8</b>	1.55 ± 0.08	1.41 ± 0.08	<b>0.046<sup>a</sup></b>	1.47 ± 0.09	1.39 ± 0.08	N	1.48 ± 0.09	1.39 ± 0.09	N

Delta: (1-3.5 Hz) / (1-12 Hz) EEG power (dB).

Theta: (4-7.5 Hz) / (1-12 Hz) EEG power (dB).

Low Alpha: (8-10 Hz) / (1-12 Hz) EEG power (dB).

High Alpha: (10.5-12 Hz) / (1-12 Hz) EEG power (dB).

*p* value: measured using Wilcoxon rank-sum test with a significant *p* value < 0.05.

1) N: Not significant (*p* ≥ 0.05).

2) Significance values were adjusted using a sharpened Bonferroni correction for multiple comparisons (primary significance level *p* < 0.05 and secondary significance level *p* < 0.025).

<sup>a</sup> Not statistically significant after Sharpened Bonferroni adjustment.

<sup>b</sup> Baseline (pretreatment) period.

<sup>c</sup> 240-min post-treatment period.

patients who actively responded to the ketamine infusion but not in those who received NS.

In summary, Table III addresses the comparisons of baseline and 240 min post-treatment within one group (intra-subject EEG variabilities), which can identify ketamine responses, and can potentially contribute to regression

analysis in the future to estimate the relationships among EEG variables.



Table IV. Performances of EEG Power Predictors

Predictors	Accuracy $\pm$ SD by EEG frequency (%)								
	Mixed Ketamine Groups			0.5 mg/Kg Ketamine Group			0.2 mg/Kg Ketamine Group		
	Theta	Low alpha	Theta + Low alpha	Theta	Low alpha	Theta + Low alpha	Theta	Low alpha	Theta + Low alpha
LDA	69.8 $\pm$ 6.5	60.2 $\pm$ 5.1	71.6 $\pm$ 7.4	70.2 $\pm$ 6.0	64.5 $\pm$ 6.0	72.1 $\pm$ 7.6	69.8 $\pm$ 6.5	60.2 $\pm$ 5.1	69.6 $\pm$ 8.7
NMSC	61.4 $\pm$ 5.4	62.5 $\pm$ 6.9	76.2 $\pm$ 9.3	65.3 $\pm$ 5.8	64.6 $\pm$ 6.3	78.3 $\pm$ 8.9	61.4 $\pm$ 5.4	62.5 $\pm$ 6.9	77.1 $\pm$ 9.0
3-NN	67.5 $\pm$ 6.5	61.1 $\pm$ 5.3	74.2 $\pm$ 9.7	68.7 $\pm$ 6.2	63.2 $\pm$ 5.8	75.2 $\pm$ 9.3	67.5 $\pm$ 6.5	61.1 $\pm$ 5.3	73.5 $\pm$ 9.1
PARZEN	67.8 $\pm$ 6.6	62.0 $\pm$ 5.8	75.9 $\pm$ 7.8	70.9 $\pm$ 6.1	63.5 $\pm$ 5.7	75.3 $\pm$ 8.0	67.8 $\pm$ 6.6	62.0 $\pm$ 5.9	74.1 $\pm$ 8.0
PERLC	60.6 $\pm$ 5.9	54.6 $\pm$ 5.4	70.4 $\pm$ 6.2	64.2 $\pm$ 6.5	59.4 $\pm$ 5.8	71.6 $\pm$ 5.9	60.6 $\pm$ 5.9	55.3 $\pm$ 6.0	69.7 $\pm$ 6.0
DRBMC	61.5 $\pm$ 6.5	57.3 $\pm$ 7.4	71.1 $\pm$ 4.7	67.3 $\pm$ 6.4	55.8 $\pm$ 7.2	73.0 $\pm$ 5.1	61.5 $\pm$ 6.5	56.4 $\pm$ 7.5	70.3 $\pm$ 5.2
SVMRBF	73.5 $\pm$ 9.5	63.1 $\pm$ 9.8	<b>81.3 <math>\pm</math> 9.5</b>	77.6 $\pm$ 8.6	69.3 $\pm$ 7.4	<b>80.6 <math>\pm</math> 8.3</b>	73.5 $\pm$ 9.5	64.3 $\pm$ 9.5	<b>78.4 <math>\pm</math> 9.6</b>

Abbreviations: LDA: linear discriminant analysis; NMSC: nearest mean classifier; 3-NN: k-nearest neighbors with k = 3; PARZEN: Parzen density estimation; PERLC: perceptron classifier; DRBMC: discriminative restricted Boltzmann machine; SVMRBF: support vector machine with radial basis function.

#### D. Performances of EEG Predictors

The classification performances (mean accuracy  $\pm$  SD) are summarized in Table IV. Specifically, we used seven machine learning classifiers (LDA, NMSC, 3-NN, PARZEN, PERLC, DRBMC and SVMRBF) to separately train a prediction model using two-thirds of the enrolled subjects ( $n = 25$ , including 11 responders and 14 non-responders) and then test the performance of the classifier using the remaining subjects ( $n = 12$ ). The significant EEG features from Table II (e.g., EEG power in relative theta or low alpha frequency band) were selected as input features.

In this study, we also considered the imbalanced problem; therefore, we randomly over-sampled 3 samples from the training dataset of the responder group to increase the samples of minority. Thus, the training dataset was balanced in the responders ( $n = 14$ ) and non-responders ( $n = 14$ ) groups. EEG features combining the relative theta with a low alpha power had the best performance with the highest accuracy (81.3  $\pm$  9.5%). The predictor with the best performance had 82.1  $\pm$  8.6% sensitivity, 91.9  $\pm$  7.4% specificity, 81.9  $\pm$  8.6% recall, 92.0  $\pm$  8.2% precision and 57.2  $\pm$  4.4% F-measure based on our SVMRBF (parameters:  $c = 10$ ,  $\gamma = 1$ ) predictor.

Then, we considered the classification performances for ketamine groups A and B separately. In terms of group A, we randomly over-sampled 2 samples from the training dataset of the non-responder group to increase the samples of minority. Thus, the training dataset was balanced in the responders ( $n = 7$ ) and non-responders ( $n = 7$ ) groups. The SVMRBF-based predictor (parameters:  $c = 10$ ,  $\gamma = 1$ ) achieved the highest 80.6  $\pm$  8.3% accuracy and 81.7  $\pm$  8.5% sensitivity, 88.3  $\pm$  7.5% specificity, 80.6  $\pm$  7.8% recall, 91.1  $\pm$  7.7% precision and 57.3  $\pm$  4.5% F-measure. In terms of group B, we randomly over-sampled 6 samples from the training dataset of the responder group to increase the samples of minority. Thus, the training dataset was balanced in the responders ( $n = 9$ ) and non-responders ( $n = 9$ ) groups. The SVMRBF-based predictor (parameters:  $c = 10$ ,  $\gamma = 1$ ) achieved the highest 78.4  $\pm$  9.6% accuracy and 79.3  $\pm$  8.8% sensitivity, 84.2  $\pm$  7.7% specificity, 78.5  $\pm$  8.0% recall, 87.0  $\pm$  7.9% precision and 52.6  $\pm$  5.5% F-measure.

If other EEG baseline features (e.g., alpha asymmetry or theta cordance) were treated as characteristic inputs to build a classification (prediction) model, the performances were

inferior to EEG power predictors. Specifically, the EEG alpha asymmetry predictors could only achieve the highest 73.1  $\pm$  9.2% accuracy, and EEG theta cordance predictors could only achieve the highest 69.5  $\pm$  8.6% accuracy. In summary, our proposed model could predict antidepressant effects after the administration of ketamine (240 min) for the purpose of distinguishing responders and non-responders at the baseline EEG power.

#### IV. DISCUSSION

Our study investigated baseline and post-ketamine infusion forehead EEG patterns in patients with TRD under randomized, double-blind, placebo-controlled conditions. The rapid antidepressant effects of low-dose ketamine are reflected by changes in the EEG power spectra and asymmetry in the prefrontal region. We differentiated responders from non-responders who received 0.5 or 0.2 mg/kg ketamine infusions based on their baseline EEG, and we explored the EEG changes in the early (240 min) post-infusion period in ketamine responders, ketamine non-responders and NS controls. According to Table III, ketamine responders displayed weaker relative EEG power in the theta bands at baseline, increased relative EEG power and decreased asymmetry in the low alpha band; these responses were correlated with the rapid antidepressant effects of ketamine. Of note, our study used machine learning technology (Table IV) and wearable EEG devices to distinguish ketamine responders from non-responders with 81.3  $\pm$  9.5% accuracy, 82.1  $\pm$  8.6% sensitivity and 91.9  $\pm$  7.4% specificity; this method may have the potential to predict rapid antidepressant effects. Our forehead EEG patterns suggested that the baseline and early changes in prefrontal activities may predict individual antidepressant responses to a mixed dose of ketamine.

The dose-related efficacy of ketamine in the current study is consistent with an earlier meta-analysis that suggested that higher ketamine doses were more effective among several studies [35]. Moreover, one study of the S-isomer of ketamine suggested that both 0.2- and 0.4-mg/kg doses were effective [36]. Nevertheless, R/S-ketamine has routinely been infused in previous studies at a dose of 0.5 mg/kg to treat depression [27, 37] but has never been tested at a lower dose (e.g., 0.2 mg/kg). Therefore, testing a lower R/S-ketamine dose to determine whether the antidepressant



efficacy would be maintained while minimizing adverse psychoactive effects, such as dissociation, would be of interest. Furthermore, according to Table I, our findings showed that 2 patients in group C responded to NS, which is the placebo effect in clinical trials. Prior studies showed that depressed patients who are treated with placebo may have substantial reductions in symptoms [38]. The placebo effect involves psychological factors, including frequent visits, the infusion procedure and care from medical staff members, along with some brain mechanisms of the placebo effect. Additionally, of particular interest, the efficacy of ketamine in Han Chinese, e.g., Taiwanese, patients [39] has been noted, but the generalizability of ketamine efficacy to populations of diverse races and ethnicities has not been established. Therefore, our study addresses this need by examining the effect of ketamine in a Taiwanese population. Our finding that Taiwanese patients may experience good antidepressant effects with a 61% response rate to the standard (0.5 mg/kg) ketamine dose is consistent with our recent adjunctive ketamine study [39].

#### A. Baseline EEG Patterns

Baseline measures of prefrontal electrical activity have been highlighted as EEG biosignatures for antidepressant responses. Theta and low alpha activity have been linked to processing functions related to emotion [40], and pretreatment theta activity has been associated with the antidepressant response localized to the anterior cingulate cortex (ACC) [41]. According to our baseline results in Table II, patients with TRD who exhibited an effective ketamine response exhibited lower relative EEG power in the theta and low alpha bands, whereas the absolute EEG power differences were not significant in any of the frequency bands. Moreover, according to our results in section III-A, the 0.5 mg/kg dose of ketamine produced better response effects than did the 0.2 mg/kg dose (response rate = 61.1% vs. 26.3% at 4 hours after treatment, respectively), which may be explained by the fact that most patients responded to the 0.5 mg/kg dose, whereas the lower dose (0.2 mg/kg) affected only some patients with weak EEG power in the theta band at baseline. In other words, patients may require a normal low dose (0.5 mg/kg) of ketamine if they have relatively weak theta waves at baseline; otherwise, they would require a slightly lower dose (0.2 mg/kg). Our baseline EEG power result is consistent with that of a previous study using selective serotonin reuptake inhibitor (SSRI) treatment [17], but it partially contrasts a study that associated fluoxetine and venlafaxine antidepressant responses with overall higher baseline EEG theta power [16]. Differences in these findings may be related to differences in the mechanisms of action between rapid antidepressants (e.g., ketamine) and conventional antidepressants. In terms of the biological mechanism derived from theta and alpha activity, lower baseline theta and alpha activity may be positively correlated with glucose metabolism in ketamine responders [42] and reflect lower arousal associated with lower serotonergic activity [18]. Additionally, a current interest in using baseline biosignatures to predict the treatment response in patients with depression has been reported [43,

44]. Prefrontal EEG power at baseline was reported to predict the SSRI antidepressant response with 63% [17] and 88% accuracy [45] in two studies using machine learning technology, suggesting that the use of forehead EEG patterns shows potential for building a baseline predictor for responses to ketamine treatment.

#### B. Early Changes in Prefrontal EEG After Ketamine Treatment

EEG is generally used to evaluate antidepressant outcomes by examining pre- to post-treatment EEG changes [44]. Using baseline relative EEG measurements and early post-treatment changes, significantly lower alpha power was observed in depressed patients compared with normal controls [46], and significantly higher alpha asymmetry was observed in depressed patients than in normal controls in previous baseline EEG studies [47]. These findings revealed EEG changes in the active ketamine group compared with normal controls. Based on our findings in Table III, early (240 min) changes in post-treatment responders, which are characterized by increased relative power and decreased asymmetry in the low alpha band, were required for the ketamine-specific rapid antidepressant effect. Our results revealed increased prefrontal alpha activity after effective responses. This finding is consistent with that of a previous study showing that elevated resting rACC activity is correlated with the ATR through adaptive self-referential functions, such as mindfulness and non-evaluative self-focus [48]. The decreased EEG asymmetry may be positively correlated with lower behavioral activation sensitivity and inversely correlated with negative affect and behavioral inhibition [47, 49]. Regarding the EEG cordance, our findings showed a decrease in theta cordance at prefrontal leads compared to that at baseline; however, this was not the case in non-responders or patients treated with placebo. This trend is similar to that in prior studies with other antidepressant treatments [24, 25].

However, although correlations between these EEG signatures and the response to antidepressant treatment have been proposed, none have been validated to date because recent findings have not been consistently replicated. Jaworska, et al. [50] reported an elevated absolute alpha power in depressed patients. This finding was replicated in a large sample with increased alpha and theta EEG power for patients in the early stages of depression [51]. Other studies failed to show decreased alpha activity in patients with TRD [46]. In addition, EEG differences have been associated with improved antidepressant treatment outcomes. For example, an increased EEG alpha power has been shown to differentiate responders from non-responders following 3 to 6 weeks of treatment with SSRIs such as paroxetine and fluoxetine [21]. Nevertheless, many studies have failed to replicate the findings of alpha asymmetry in depression [20, 46]. In addition to alpha activity measures, one prognostic study reported that the reduced theta power was related to a response to antidepressant treatments [17]. Conversely, increased theta activity has been observed in responders at 6 weeks after treatment with SSRIs [52]. These studies are limited due to the mixed results for the criteria of the theta

and alpha activity associated with different antidepressant responses.

### C. Ketamine Outcome Prediction

Current research has focused on using baseline patterns to predict treatment response in depression [43, 44]. Abnormalities in theta and alpha EEG activities have been associated with major depression [11, 12, 15, 16, 18], which suggests that the EEG parameters of theta and alpha bands have significant biosignatures and offer the potential to build a baseline predictor. One prior study reported that baseline prefrontal relative theta power could predict antidepressant response to SSRI with 63% accuracy [17]. Another more recent study reported that baseline prediction improved to 87.9% accuracy for SSRI treatment using machine-learning technology and various patterns [45]. The baseline results of our study (Table IV) provided the patterns of relative theta and low alpha EEG power to predict the effect of ketamine with  $81.3 \pm 9.5\%$  accuracy,  $82.1 \pm 8.6\%$  sensitivity and  $91.9 \pm 7.4\%$  specificity based on the SVMRBF predictor. This baseline EEG predictor may offer a supporting reference to help doctors select an appropriate ketamine dose for depressed patients.

Ketamine treatment, in contrast to traditional antidepressants, can reduce depressive symptoms rapidly within 4 hours post-treatment. Considering the rapid effects of ketamine observed in our manuscript, we labeled responders and non-responders at 4 hours post-treatment. If we labeled responders and non-responders at other time instances, e.g., after 4 hours post-treatment, the numbers of responders would decrease instantly due to the reduced effects of ketamine; therefore, this methodology is not considered an optimized label and training model, accounting for the unbalanced samples after 4 hours post-treatment (e.g., increasing numbers of responders and decreasing numbers of non-responders).

### D. Wearable Forehead EEG with Dry Sensors

Notably, the identified EEG signatures have the potential to distinguish ketamine responders and non-responders at baseline and to predict the levels of antidepressant response to ketamine with further clinical usage. With the development of sensor technology, an alternative to conventional EEG devices with wet electrodes and cables has emerged. Wearable and wireless EEG devices with dry-contact sensors (Fig. 1-A) have led to a reduction in the amount of preparatory work required for long-term monitoring and daily use [13, 14, 53] and have successfully monitored brain activity in sleep and driving experiments [54, 55]. Wearable wireless EEG devices with dry sensors offer a promising tool for the everyday monitoring of depression. Forehead EEG patterns could potentially be used to estimate ketamine responses in daily life via a wearable EEG-based system.

### E. Limitations

The major strength of this study was the sizeable number of patients tested using a randomized and placebo-controlled

design. However, this study also had limitations. First, responders were defined as subjects with at least a 45% reduction in baseline depression symptoms (HDRS-17) instead of the popular criterion of a 50% reduction, as the sample size of the latter was too small to conduct statistical analysis. Furthermore, we combined the data from groups A and B in the analysis because of the small number of responders in group B. In the future, we would overcome this problem by increasing the total number of participants in each dose group to obtain a better comparison of the responders at each dose. Second, recruitment for the study was limited to Asian patients with TRD, which may yield results that cannot be generalized to other populations. Wider application would require a broader range of participants of different races. Third, none of our participants reported a significant effect of traditional antidepressant treatments; therefore, EEG dynamics were primarily influenced by the effect of ketamine. Nevertheless, EEG changes may be affected by the concomitant use of other antidepressant treatments. Fourth, the results of the present study provide evidence to support the involvement of EEG power and asymmetry in the low alpha band on the 240-min antidepressant effects of a single-dose ketamine treatment in patients with TRD. However, further research is required to determine how the changes in EEG power and asymmetry relate to the antidepressant effects of ketamine at other time points (days 2, 3, 4, etc.). Lastly, as our wearable headband-style EEG equipment is limited by the placement of electrodes (prefrontal area), this device is not feasible for covering the entire brain. Thus, our findings represent only regional specificity for prefrontal EEG dynamics. We are unsure whether the effects of ketamine could also involve EEG dynamics in other brain regions (e.g., parietal or occipital cortices). Due to this limitation of the electrode placements, we plan to use a multichannel EEG device to obtain a wider range of brain signals in the future.

## V. CONCLUSION

Our randomized, double-blind, placebo-controlled study revealed the EEG patterns at baseline and in response to a mixed-dose ketamine treatment in patients with TRD. The results provided initial evidence that the ketamine responders had weaker baseline EEG theta power and thus functioned as an EEG-based predictor with  $81.3 \pm 9.5\%$  accuracy,  $82.1 \pm 8.6\%$  sensitivity and  $91.9 \pm 7.4\%$  specificity. Moreover, an active ketamine response was accompanied by increased alpha power and decreased alpha asymmetry. In addition, Taiwanese patients may exhibit a good antidepressant response to the standard (0.5 mg/kg) ketamine dose. These insights provide important information about potential targets for the baseline identification of ketamine responders and the underpinnings of the early effects of ketamine on TRD.

## ACKNOWLEDGEMENT

We express our gratitude to all the patients who kindly participated in this study. In addition, we thank all the research assistants (Hui-Ju Wu and Chia-Min Huang), physicians, and pharmacists as well as the nursing staff at the D020 Unit of Taipei Veterans General Hospital for their assistance during the study process; without them, this work would not have been possible. We also greatly appreciate Dr. Guang Cheng for providing excellent opinions on our work.

## REFERENCES

- [1] C. Wijeratne and P. Sachdev, "Treatment-resistant depression: critique of current approaches," *Australian & New Zealand Journal of Psychiatry*, vol. 42, pp. 751-762, 2008.
- [2] S. J. Mathew, A. Shah, K. Lapidus, C. Clark, N. Jarun, B. Ostermeyer, *et al.*, "Ketamine for treatment-resistant unipolar depression," *CNS drugs*, vol. 26, pp. 189-204, 2012.
- [3] G. L. Larkin and A. L. Beautrais, "A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department," *The International Journal of Neuropsychopharmacology*, vol. 14, pp. 1127-1131, 2011.
- [4] C. T. Li, M. H. Chen, W. C. Lin, C. J. Hong, B. H. Yang, R. S. Liu, *et al.*, "The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study," *Human brain mapping*, vol. 37, pp. 1080-1090, 2016.
- [5] J. L. Price and W. C. Drevets, "Neurocircuitry of mood disorders," *Neuropsychopharmacology*, vol. 35, pp. 192-216, 2010.
- [6] K. Goldapple, Z. Segal, C. Garson, M. Lau, P. Bieling, S. Kennedy, *et al.*, "Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy," *Archives of general psychiatry*, vol. 61, pp. 34-41, 2004.
- [7] C.-C. Chang, S.-C. Yu, D. R. McQuoid, D. F. Messer, W. D. Taylor, K. Singh, *et al.*, "Reduction of dorsolateral prefrontal cortex gray matter in late-life depression," *Psychiatry Research: Neuroimaging*, vol. 193, pp. 1-6, 2011.
- [8] C.-T. Li, S.-J. Wang, J. Hirvonen, J.-C. Hsieh, Y.-M. Bai, C.-J. Hong, *et al.*, "Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism," *Journal of affective disorders*, vol. 127, pp. 219-229, 2010.
- [9] C.-T. Li, C.-P. Lin, K.-H. Chou, I.-Y. Chen, J.-C. Hsieh, C.-L. Wu, *et al.*, "Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study," *Neuroimage*, vol. 50, pp. 347-356, 2010.
- [10] E. Niedermeyer and F. L. da Silva, *Electroencephalography: basic principles, clinical applications, and related fields*: Lippincott Williams & Wilkins, 2005.
- [11] A. Baskaran, R. Milev, and R. S. McIntyre, "The neurobiology of the EEG biomarker as a predictor of treatment response in depression," *Neuropharmacology*, vol. 63, pp. 507-513, 2012.
- [12] S. Olbrich and M. Arns, "EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response," *International Review of Psychiatry*, vol. 25, pp. 604-618, 2013.
- [13] B. C.-T. Lin, L.-W. Ko, J.-C. Chiou, J.-R. Duann, R.-S. Huang, S.-F. Liang, *et al.*, "Noninvasive neural prostheses using mobile and wireless EEG," *Proceedings of the IEEE*, vol. 96, pp. 1167-1183, 2008.
- [14] L.-D. Liao, C.-T. Lin, K. McDowell, A. E. Wickenden, K. Gramann, T.-P. Jung, *et al.*, "Biosensor technologies for augmented brain-computer interfaces in the next decades," *Proceedings of the IEEE*, vol. 100, pp. 1553-1566, 2012.
- [15] M. Arns, W. H. Drinkenburg, P. B. Fitzgerald, and J. L. Kenemans, "Neurophysiological predictors of non-response to rTMS in depression," *Brain Stimulation*, vol. 5, pp. 569-576, 2012.
- [16] I. A. Cook, A. F. Leuchter, M. Morgan, E. Witte, W. F. Stubbeman, M. Abrams, *et al.*, "Early changes in prefrontal activity characterize clinical responders to antidepressants," *Neuropsychopharmacology*, vol. 27, pp. 120-131, 2002.
- [17] D. V. Iosifescu, S. Greenwald, P. Devlin, D. Mischoulon, J. W. Denninger, J. E. Alpert, *et al.*, "Frontal EEG predictors of treatment outcome in major depressive disorder," *European Neuropsychopharmacology*, vol. 19, pp. 772-777, 2009.
- [18] G. E. Bruder, J. P. Sedoruk, J. W. Stewart, P. J. McGrath, F. M. Quitkin, and C. E. Tenke, "Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre-and post-treatment findings," *Biological psychiatry*, vol. 63, pp. 1171-1177, 2008.
- [19] D. N. Towers and J. J. Allen, "A better estimate of the internal consistency reliability of frontal EEG asymmetry scores," *Psychophysiology*, vol. 46, pp. 132-142, 2009.
- [20] C. Gold, J. FACHNER, and J. ERKKILÄ, "Validity and reliability of electroencephalographic frontal alpha asymmetry and frontal midline theta as biomarkers for depression," *Scandinavian Journal of Psychology*, vol. 54, pp. 118-126, 2013.
- [21] G. E. Bruder, J. W. Stewart, C. E. Tenke, P. J. McGrath, P. Leite, N. Bhattacharya, *et al.*, "Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant," *Biological psychiatry*, vol. 49, pp. 416-425, 2001.
- [22] D. Spronk, M. Arns, K. Barnett, N. Cooper, and E. Gordon, "An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study," *Journal of affective disorders*, vol. 128, pp. 41-48, 2011.
- [23] A. F. Leuchter, I. A. Cook, R. B. Lufkin, J. Dunkin, T. F. Newton, J. L. Cummings, *et al.*, "Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography," *Neuroimage*, vol. 1, pp. 208-219, 1994.
- [24] M. Bares, M. Brunovsky, M. Kopecek, P. Stopkova, T. Novak, J. Kozeny, *et al.*, "Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study," *Journal of Psychiatric Research*, vol. 41, pp. 319-325, 2007.
- [25] M. Bares, M. Brunovsky, M. Kopecek, T. Novak, P. Stopkova, J. Kozeny, *et al.*, "Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder," *European Psychiatry*, vol. 23, pp. 350-355, 2008.
- [26] T. M. Itil, "The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG)," *Progress in neurobiology*, vol. 20, pp. 185-249, 1983.
- [27] R. M. Berman, A. Cappiello, A. Anand, D. A. Oren, G. R. Heninger, D. S. Charney, *et al.*, "Antidepressant effects of ketamine in depressed patients," *Biological psychiatry*, vol. 47, pp. 351-354, 2000.
- [28] C. A. Zarate, J. B. Singh, P. J. Carlson, N. E. Brutsche, R. Ameli, D. A. Luckenbaugh, *et al.*, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression," *Archives of general psychiatry*, vol. 63, pp. 856-864, 2006.
- [29] J. W. Murrough, A. M. Perez, S. Pillemer, J. Stern, M. K. Parides, M. aan het Rot, *et al.*, "Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression," *Biological psychiatry*, vol. 74, pp. 250-256, 2013.
- [30] D. V. Sheehan, Y. Lecrubier, K. H. Sheehan, P. Amorim, J. Janavs, E. Weiller, *et al.*, "The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10," *Journal of clinical psychiatry*, 1998.
- [31] M. Hamilton, "Development of a rating scale for primary depressive illness," *British journal of social and clinical psychology*, vol. 6, pp. 278-296, 1967.
- [32] C.-T. Lin, C.-S. Huang, W.-Y. Yang, A. K. Singh, C.-H. Chuang, and Y.-K. Wang, "Real-Time EEG Signal Enhancement Using

- Canonical Correlation Analysis and Gaussian Mixture Clustering," *Journal of Healthcare Engineering*, vol. 2018, 2018.
- [33] A. Delorme and S. Makeig, "EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis," *Journal of neuroscience methods*, vol. 134, pp. 9-21, 2004.
- [34] Y. Hochberg, "A sharper Bonferroni procedure for multiple tests of significance," *Biometrika*, vol. 75, pp. 800-802, 1988.
- [35] Y. Xu, M. Hackett, G. Carter, C. Loo, V. Gálvez, N. Glozier, *et al.*, "Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis," *International Journal of Neuropsychopharmacology*, vol. 19, p. pyv124, 2015.
- [36] J. B. Singh, M. Fedgchin, E. Daly, L. Xi, C. Melman, G. De Bruecker, *et al.*, "Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study," *Biological psychiatry*, vol. 80, pp. 424-431, 2016.
- [37] T. Kishimoto, J. Chawla, K. Hagi, C. Zarate, J. Kane, M. Bauer, *et al.*, "Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories," *Psychological medicine*, vol. 46, pp. 1459-1472, 2016.
- [38] F. M. Quitkin, "Placebos, drug effects, and study design: a clinician's guide," *American Journal of Psychiatry*, vol. 156, pp. 829-836, 1999.
- [39] T.-P. Su, M.-H. Chen, C.-T. Li, W.-C. Lin, C.-J. Hong, R. Gueorguieva, *et al.*, "Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression," *Neuropsychopharmacology*, 2017.
- [40] L. Aftanas and S. Golocheikine, "Human anterior and frontal midline theta and lower alpha reflect emotionally positive state and internalized attention: high-resolution EEG investigation of meditation," *Neuroscience letters*, vol. 310, pp. 57-60, 2001.
- [41] D. Pizzagalli, R. D. Pascual-Marqui, J. B. Nitschke, T. R. Oakes, C. L. Larson, H. C. Abercrombie, *et al.*, "Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis," *American Journal of Psychiatry*, vol. 158, pp. 405-415, 2001.
- [42] D. A. Pizzagalli, T. R. Oakes, and R. J. Davidson, "Coupling of theta activity and glucose metabolism in the human rostral anterior cingulate cortex: an EEG/PET study of normal and depressed subjects," *Psychophysiology*, vol. 40, pp. 939-949, 2003.
- [43] C. J. Harmer, "Neural Predictors of Treatment Response in Depression," *Current Behavioral Neuroscience Reports*, vol. 1, pp. 125-133, 2014.
- [44] A. M. Hunter, I. A. Cook, and A. F. Leuchter, "The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder," *Psychiatric Clinics of North America*, vol. 30, pp. 105-124, 2007.
- [45] A. Khodayari-Rostamabad, J. P. Reilly, G. M. Hasey, H. de Bruin, and D. J. MacCrimmon, "A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder," *Clinical Neurophysiology*, vol. 124, pp. 1975-1985, 2013.
- [46] G. Price, J. Lee, C. Garvey, and N. Gibson, "Appraisal of sessional EEG features as a correlate of clinical changes in an rTMS treatment of depression," *Clinical EEG and neuroscience*, vol. 39, pp. 131-138, 2008.
- [47] J. K. Gollan, D. Hoxha, D. Chihade, M. E. Pflieger, L. Rosebrock, and J. Cacioppo, "Frontal alpha EEG asymmetry before and after behavioral activation treatment for depression," *Biological psychology*, vol. 99, pp. 198-208, 2014.
- [48] D. A. Pizzagalli, "Frontocingulate dysfunction in depression: toward biomarkers of treatment response," *Neuropsychopharmacology*, vol. 36, pp. 183-206, 2011.
- [49] E. Jesulola, C. F. Sharpley, V. Bitsika, L. L. Agnew, and P. Wilson, "Frontal alpha asymmetry as a pathway to behavioural withdrawal in depression: Research findings and issues," *Behavioural brain research*, vol. 292, pp. 56-67, 2015.
- [50] N. Jaworska, P. Blier, W. Fusee, and V. Knott, "Alpha power, alpha asymmetry and anterior cingulate cortex activity in depressed males and females," *Journal of psychiatric research*, vol. 46, pp. 1483-1491, 2012.
- [51] V. A. Grin-Yatsenko, I. Baas, V. A. Ponomarev, and J. D. Kropotov, "Independent component approach to the analysis of EEG recordings at early stages of depressive disorders," *Clinical Neurophysiology*, vol. 121, pp. 281-289, 2010.
- [52] V. Knott, C. Mahoney, S. Kennedy, and K. Evans, "Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome," *Pharmacopsychiatry*, vol. 33, pp. 201-205, 2000.
- [53] C.-T. Lin, L.-D. Liao, Y.-H. Liu, I.-J. Wang, B.-S. Lin, and J.-Y. Chang, "Novel dry polymer foam electrodes for long-term EEG measurement," *Biomedical Engineering, IEEE Transactions on*, vol. 58, pp. 1200-1207, 2011.
- [54] C.-T. Lin, C.-H. Chuang, C.-S. Huang, S.-F. Tsai, S.-W. Lu, Y.-H. Chen, *et al.*, "Wireless and wearable EEG system for evaluating driver vigilance," *Biomedical Circuits and Systems, IEEE Transactions on*, vol. 8, pp. 165-176, 2014.
- [55] C.-S. Huang, C.-L. Lin, L.-W. Ko, S.-Y. Liu, T.-P. Su, and C.-T. Lin, "Knowledge-based identification of sleep stages based on two forehead electroencephalogram channels," *Frontiers in Neuroscience*, vol. 8, p. 263, 2014.